Analysts Expect GALAPAGOS NV/S (NASDAQ:GLPG) Will Announce Quarterly Sales of $173.84 Million

Equities analysts expect that GALAPAGOS NV/S (NASDAQ:GLPG) will announce sales of $173.84 million for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for GALAPAGOS NV/S’s earnings. The lowest sales estimate is $44.80 million and the highest is $465.57 million. GALAPAGOS NV/S reported sales of $119.99 million in the same quarter last year, which indicates a positive year over year growth rate of 44.9%. The business is scheduled to issue its next earnings report on Friday, October 25th.

According to Zacks, analysts expect that GALAPAGOS NV/S will report full year sales of $658.45 million for the current fiscal year, with estimates ranging from $210.56 million to $1.05 billion. For the next financial year, analysts expect that the firm will post sales of $525.69 million, with estimates ranging from $131.04 million to $779.86 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for GALAPAGOS NV/S.

A number of research analysts have issued reports on the stock. Cowen reaffirmed a “buy” rating on shares of GALAPAGOS NV/S in a report on Friday, July 26th. Royal Bank of Canada raised their target price on shares of GALAPAGOS NV/S to $171.00 in a research report on Monday, July 29th. Stifel Nicolaus raised their target price on shares of GALAPAGOS NV/S from $121.00 to $188.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Zacks Investment Research upgraded shares of GALAPAGOS NV/S from a “hold” rating to a “buy” rating and set a $152.00 target price on the stock in a research report on Wednesday, July 10th. Finally, Nomura raised their target price on shares of GALAPAGOS NV/S from $140.00 to $209.00 and gave the stock a “buy” rating in a research report on Monday, July 29th. Three research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $156.45.



NASDAQ GLPG traded down $1.02 during trading hours on Friday, hitting $173.87. 78,393 shares of the stock were exchanged, compared to its average volume of 133,223. The company has a market cap of $8.93 billion, a P/E ratio of -263.67 and a beta of 1.57. GALAPAGOS NV/S has a 12-month low of $85.00 and a 12-month high of $191.63. The stock has a 50-day moving average of $159.14. The company has a current ratio of 6.40, a quick ratio of 6.40 and a debt-to-equity ratio of 0.02.

Several hedge funds have recently modified their holdings of GLPG. Norges Bank purchased a new stake in GALAPAGOS NV/S during the 4th quarter worth $6,422,000. Henry James International Management Inc. increased its stake in GALAPAGOS NV/S by 3.7% during the 1st quarter. Henry James International Management Inc. now owns 20,719 shares of the biotechnology company’s stock worth $2,440,000 after buying an additional 740 shares during the period. Millennium Management LLC grew its holdings in GALAPAGOS NV/S by 14.6% during the 4th quarter. Millennium Management LLC now owns 72,538 shares of the biotechnology company’s stock worth $6,655,000 after acquiring an additional 9,217 shares in the last quarter. Alps Advisors Inc. grew its holdings in GALAPAGOS NV/S by 14.5% during the 1st quarter. Alps Advisors Inc. now owns 87,116 shares of the biotechnology company’s stock worth $10,261,000 after acquiring an additional 11,045 shares in the last quarter. Finally, Bessemer Group Inc. acquired a new position in GALAPAGOS NV/S during the 2nd quarter worth $48,447,000. 17.06% of the stock is currently owned by institutional investors and hedge funds.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Recommended Story: How does quantitative easing work?

Get a free copy of the Zacks research report on GALAPAGOS NV/S (GLPG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.